Joshua SK Bell

Company: Tempus

Job title: Senior Director, Data Solutions

Seminars:

Beyond G12: Comprehensive RAS Biomarker Strategy and Clinical Development 10:15 am

KRAS, HRAS, and NRAS amplifications, over-expression, and mutations, in addition to tumor immune microenvironment factors that may influence  response to RAS neoantigen vaccines, reveal critical insights for targeted therapy development Tempus’ multimodal, de-identified data and certain assays can help identify a broad set of biomarkers in responsive patients Gain perspective on the significance of RAS…Read more

day: Day One